112 related articles for article (PubMed ID: 28520447)
1. [Controversies around QALYs].
Rogalewicz V; Barták M
Vnitr Lek; 2017; 63(4):242-248. PubMed ID: 28520447
[TBL] [Abstract][Full Text] [Related]
2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
Griebsch I; Coast J; Brown J
Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
[TBL] [Abstract][Full Text] [Related]
3. Controversy Over Using Quality-Adjusted Life-Years In Cost-Effectiveness Analyses: A Systematic Literature Review.
Rand LZ; Kesselheim AS
Health Aff (Millwood); 2021 Sep; 40(9):1402-1410. PubMed ID: 34495724
[TBL] [Abstract][Full Text] [Related]
4. [QALYS or not QALYS: that is the question?].
Moatti JP; Auquier P; Le Coroller AG; Macquart-Moulin G
Rev Epidemiol Sante Publique; 1995 Dec; 43(6):573-83. PubMed ID: 8552855
[TBL] [Abstract][Full Text] [Related]
5. The Corrective Approach: Policy Implications of Recent Developments in QALY Measurement Based on Prospect Theory.
Lipman SA; Brouwer WBF; Attema AE
Value Health; 2019 Jul; 22(7):816-821. PubMed ID: 31277829
[TBL] [Abstract][Full Text] [Related]
6. Understanding quality-adjusted life years and their application to pharmacoeconomic research.
Raisch DW
Ann Pharmacother; 2000; 34(7-8):906-14. PubMed ID: 10928403
[TBL] [Abstract][Full Text] [Related]
7. On future non-medical costs in economic evaluations.
Liljas B; Karlsson GS; Stålhammar NO
Health Econ; 2008 May; 17(5):579-91. PubMed ID: 17787027
[TBL] [Abstract][Full Text] [Related]
8. Problems and solutions in calculating quality-adjusted life years (QALYs).
Prieto L; Sacristán JA
Health Qual Life Outcomes; 2003 Dec; 1():80. PubMed ID: 14687421
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of embryo transfer strategies: a decision analytic model using long-term costs and consequences of singletons and multiples born as a consequence of IVF.
van Heesch MM; van Asselt AD; Evers JL; van der Hoeven MA; Dumoulin JC; van Beijsterveldt CE; Bonsel GJ; Dykgraaf RH; van Goudoever JB; Koopman-Esseboom C; Nelen WL; Steiner K; Tamminga P; Tonch N; Torrance HL; Dirksen CD
Hum Reprod; 2016 Nov; 31(11):2527-2540. PubMed ID: 27907897
[TBL] [Abstract][Full Text] [Related]
10. Reconciliation of economic concerns and health policy: illustration of an equity adjustment procedure using proportional shortfall.
Stolk EA; van Donselaar G; Brouwer WB; Busschbach JJ
Pharmacoeconomics; 2004; 22(17):1097-107. PubMed ID: 15612829
[TBL] [Abstract][Full Text] [Related]
11. QALYs and mental health care.
Chisholm D; Healey A; Knapp M
Soc Psychiatry Psychiatr Epidemiol; 1997 Feb; 32(2):68-75. PubMed ID: 9050347
[TBL] [Abstract][Full Text] [Related]
12. Corneal Collagen Cross-Linking in the Management of Keratoconus in Canada: A Cost-Effectiveness Analysis.
Leung VC; Pechlivanoglou P; Chew HF; Hatch W
Ophthalmology; 2017 Aug; 124(8):1108-1119. PubMed ID: 28457614
[TBL] [Abstract][Full Text] [Related]
13. Health outcomes in economic evaluation: the QALY and utilities.
Whitehead SJ; Ali S
Br Med Bull; 2010; 96():5-21. PubMed ID: 21037243
[TBL] [Abstract][Full Text] [Related]
14. Inquiry into the relationship between equity weights and the value of the QALY.
Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
Value Health; 2012 Dec; 15(8):1119-26. PubMed ID: 23244815
[TBL] [Abstract][Full Text] [Related]
15. QALYs and carers.
Al-Janabi H; Flynn TN; Coast J
Pharmacoeconomics; 2011 Dec; 29(12):1015-23. PubMed ID: 22077576
[TBL] [Abstract][Full Text] [Related]
16. Alternatives to the quality-adjusted life year: How well do they address common criticisms?
Rand LZ; Melendez-Torres GJ; Kesselheim AS
Health Serv Res; 2023 Apr; 58(2):433-444. PubMed ID: 36537647
[TBL] [Abstract][Full Text] [Related]
17. Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project.
Beresniak A; Medina-Lara A; Auray JP; De Wever A; Praet JC; Tarricone R; Torbica A; Dupont D; Lamure M; Duru G
Pharmacoeconomics; 2015 Jan; 33(1):61-9. PubMed ID: 25230587
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared to episodic in-hospital treatment or continuous antiarrhythmic drug therapy.
Saborido CM; Hockenhull J; Bagust A; Boland A; Dickson R; Todd D
Health Technol Assess; 2010 Jun; 14(31):iii-iv, 1-75. PubMed ID: 20569652
[TBL] [Abstract][Full Text] [Related]
19. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
Beresniak A; Dupont D
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
[TBL] [Abstract][Full Text] [Related]
20. Community or patient preferences for cost-effectiveness of cardiac rehabilitation: does it matter?
Oldridge N; Furlong W; Perkins A; Feeny D; Torrance GW
Eur J Cardiovasc Prev Rehabil; 2008 Oct; 15(5):608-15. PubMed ID: 18800005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
